

type of report	Current report
number	45/2012
date of publication	2012-08-22 11:19:43
company	PHARMENA

#### **Establishing issue price of series C shares**

The Management Board of PHARMENA S.A. informs that on 22<sup>nd</sup> August 2012, a meeting of Supervisory Board took place.

Pursuant to resolution no. 3 adopted on 21<sup>st</sup> August 2012 during Extraordinary General Meeting of Pharmena S.A. on the Company's share capital increase through the issue of series C bearer shares through private placement with pre-emptive rights for hitherto shareholders and the change to the Company's Articles of Association, the Management Board, having obtained the consent of the Supervisory Board expressed in resolution no. 1/2012 of 22<sup>nd</sup> August 2012, established the issue price of series C ordinary bearer shares at 6.50 PLN (say: six PLN 50/100) per 1 share.

The goal of the issue is to obtain funds for further clinical trials of innovative anti-atherosclerosis medicinal product 1-MNA.

The information is made public due to the fact that the goal of the public offering of series C shares with pre-emptive rights is to obtain funds for further clinical trials of anti-atherosclerosis medicinal product 1-MNA, the results of which may have significant influence on the Issuer's financial and economic situation.

Legal basis: Alternative Trading System Rules – Exhibit 3 “Current and Periodical Information in the Alternative Trading System on the NewConnect Market”, Article 3 (1).

#### **Representatives of the company:**

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board